Takeda receives authorisation for three new type 2 diabetes therapies
Trelagliptin, an orally active CD26 antigen (dipeptidyl peptidase IV, DPP IV) antagonist, was being developed by Takeda, for the treatment of type 2 diabetes
Dr James Garner, General Manager for TGRD Asia said, "We are very pleased and excited that the TAK-875 study has entered Phase III trials in this region. The data published inThe Lancetis very encouraging and TAK-875 is a potential therapy for the treatme...
Marketed Type 2 diabetes mellitus Most Recent Events 09 Mar 2022 Launched for Type 2 diabetes mellitus in Thailand (PO) 26 Feb 2021 Takeda divests alogliptin/pioglitazone to Teijin Pharma in Japan 08 May 2020 Allergan has been acquired and merged into AbbVie You need to be a logged ...
Alogliptin, which was discovered by Takedaâs wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of type 2 diabetes. By providing complementary mechanisms of action, alogliptin/ACTOS targets the core defect...
(DPP-4) inhibitor for the treatment of type 2 diabetes. By providing complementary mechanisms of action, alogliptin/ACTOS targets the core defects of type 2 diabetes - insulin resistance (when the body does not efficiently use the insulin it produces) and insulin deficiency (when the ...
Type 2 diabetes (T2D) and obesity represent major challenges for global public health. They are at the forefront of international efforts to id... Mary,E.,Travers,... - 《Human Genetics》 被引量: 222发表: 2011年 Norovirus Infections in Symptomatic and Asymptomatic Food Handlers in Japan Noro...
PDG11: \\{HEALTH\\} \\{AND\\} \\{ECONOMIC\\} \\{OUTCOMES\\} \\{OF\\} A \\{NEW\\} \\{ORAL\\} \\{DIABETES\\} DRUG, \\{PIOGLITAZONE\\} (ACTOS*NF, TAKEDA), \\{IN\\} \\{THE\\} \\{MANAGEMENT\\} \\{OF\\} \\{TYPE\\} 2 \\{DIABETES\\} \\{MELLITUS\\} ...
Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated. Embryo-fetal toxicity: Based on the me...
For example, islet cells of the pancreas may be incorporated into the hydrogel compositions and implanted to achieve glucose regulation by appropriate secretion of insulin to treat diabetes. Cells from other endocrine tissues can also be implanted. The instant hydrogels can be used to provide ...